Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa

BMC Infect Dis. 2006 Feb 21:6:31. doi: 10.1186/1471-2334-6-31.

Abstract

Background: To apply clarithromycin as an immunomodulatory treatment in experimental urosepsis by multidrug-resistant Pseudomonas aeruginosa.

Methods: Acute pyelonephritis was induced in 40 rabbits after inoculation of the test isolate in the renal pelvis. Therapy was administered upon signs of sepsis in four groups: A, controls; B, intravenous clarithromycin; C, amikacin; and D, both agents. Survival and vital signs were recorded; blood was sampled for culture and estimation of pro-inflammatory mediators; monocytes were isolated for determination of apoptotic rate and ex vivo TNFalpha secretion. Quantitative cultures and biopsies of organs were performed after death.

Results: Increased rectal temperature and oxygen saturation were found in groups B and D compared to A and C. Mean survival of groups A, B, C and D was 2.65, 7.15, 4.25 and 8.70 days respectively. No differences were noted between groups concerning bacterial load in blood and tissues and serum endotoxins. Serum MDA and total caspase-3 activity of monocytes of group D decreased following treatment compared to other groups. Negative correlation was detected between cytoplasmic caspase-3 and ex vivo secretion of TNFalpha of blood monocytes of group A; similar correlation was not found for any other group. Pathology scores of liver and lung of group B were lower than group A.

Conclusion: Clarithromycin administered late in experimental urosepsis by multidrug-resistant P. aeruginosa prolonged survival and ameliorated clinical findings. Its effect is probably attributed to immunomodulatory intervention on blood monocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amikacin / therapeutic use
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Clarithromycin / administration & dosage*
  • Clarithromycin / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Multiple, Bacterial*
  • Drug Synergism
  • Drug Therapy, Combination
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Kidney / microbiology
  • Kidney / pathology
  • Lipopolysaccharides / blood
  • Liver / microbiology
  • Liver / pathology
  • Lung / microbiology
  • Lung / pathology
  • Male
  • Malondialdehyde / blood
  • Monocytes / drug effects
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects
  • Pyelonephritis / drug therapy*
  • Rabbits
  • Spleen / microbiology
  • Spleen / pathology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Bacterial Agents
  • Immunologic Factors
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Malondialdehyde
  • Amikacin
  • Clarithromycin